Aims: To assess the prevalence of elevated liver enzymes in adults with type 1 diabetes mellitus (T1DM) in routine clinical care and the association with cardiovascular risk profile in the Diabetes-Prospective-Documentation (DPV) network in Germany and Austria.
| INTRODUCTION
The clinical management of Type 1 diabetes mellitus (T1DM) focuses on preventing and treating acute, as well as chronic, complications by optimizing glycaemic control and tackling additional risk factors. This includes routine screening for nephropathy, retinopathy and neuropathy to allow early secondary prevention. 1 Annual assessment of liver function is recommended in diabetes clinical practice guidelines 1 because diabetes mellitus doubles the risk of chronic non-alcoholic fatty liver disease (NAFLD) and hepatocellular carcinoma. 2, 3 Type 2 diabetes and NAFLD share insulin resistance/hyperinsulinaemia as underlying pathophysiology; therefore, NAFLD is a well documented comorbidity of type 2 diabetes. [4] [5] [6] In contrast, the clinical significance of measuring liver enzymes in T1DM as part of the annual screening for complications is unclear;
T1DM is an autoimmune condition with absolute insulin deficiency and usually is not accompanied per se by features of metabolic syndrome. However, the prevalence of the metabolic syndrome is increasing in both the general population, and in individuals with T1DM. 7 The cardiovascular risk profile in individuals with T1DM
demands prescription of drugs that can have hepatotoxic side effects.
The real-life clinical practice of routinely measuring liver enzymes, as well as the prevalence of increased liver enzymes in individuals with T1DM in routine clinical care, have not as yet been documented in larger surveys. Therefore, it seemed timely to assess the prevalence of elevated liver enzymes in adults with T1DM in a cross sectional multicentre and multinational clinical audit database.
Further, we wanted to investigate associations between increased liver enzymes, glycaemic control, cardiovascular risk profile and late complications of diabetes in individuals with T1DM.
| SUBJECTS AND METHODS

| Data collection
The German/Austrian Diabetes Patienten Verlaufsdokumentation (DPV) prospective documentation system is a nationwide multicentre register 8 9 A detailed flow-chart is provided in Figure 1 . 
| Comorbidities and complications
Hypertension was defined as the use of antihypertensive medication or as increased systolic (≥140 mm Hg) and/or diastolic (≥90 mm Hg) arterial blood pressure according to current guidelines. 13 
| Subgroup analyses
In order to address the issue of potential heterogeneity among centres, concerning the frequency with which they measure liver enzymes, we conducted 2 additional analyses to better understand the data set available. We compared data from centres in which liver enzymes were measured in more than 50% of patients with data from centres that conduct less frequent measurements. A comparison was made between patients for whom liver enzymes were available and those patients whose liver enzymes were not measured/ reported. The results are provided online (Appendix S3).
| Statistical analyses
Statistical analyses were performed using the software package SAS and multiple linear regression analyses for continuous variables (age, BMI, HbA1c, insulin doses) were applied for adjustment.
| RESULTS
Data on liver enzymes from the previous 12 months were available from 270 centres. A total of 9226 patients (29%) of the 32 075 patients fulfilling inclusion criteria underwent liver transaminase measurement and this was reported at least once in the 12-month observation period (Figure 1 ). Of the 270 centres that were reporting liver enzyme measurements, 83 centres measured liver enzymes in at least 50% of their patients (Table S2 ).
| Total cohort
More than half (56%) of the patients were undergoing intensified basis bolus insulin therapy using insulin pens; an additional 29% were using insulin pumps and 15% were undergoing conventional insulin therapy. In this cohort there is a high proportion of well-controlled patients (40% with HbA1c ≤ 7.5%), but 33% have an HbA1c level above 9% ( 
| Subgroup comparison between patients with increased and normal liver enzymes
Characteristics of both groups (patients with increased liver enzymes and those with normal liver enzymes) are shown in Table 1 . Patients with increased liver enzymes were older, had a higher BMI (both P values < .0001) and larger waist circumference (P < .0005) than patients with normal liver enzymes, while duration of diabetes, sex distribution and proportion of individuals with a background of migration did not differ ( Table 1 ). The group with increased liver enzymes had worse glycaemic control (P < .00001), a higher proportion of patients undergoing conventional insulin therapy and a lower proportion of patients undergoing intensified or insulin pump therapy than the group with normal liver enzyme levels (all P values < 0.01) ( Table 1) . Lipid modifying drugs were taken by 19% in the group with normal liver enzymes and 29% in the group with increased liver enzymes (both P values < .00001).
After adjustment for age, sex, HbA1c, diabetes duration, migration background and treatment centre in linear regression models, age, BMI, HbA1c and daily insulin dose per body weight were significantly higher in the group with increased liver enzymes than in the group with normal liver enzymes (all adjusted values are presented in Table 2 ; corresponding P values < .0001) ( (Table S2 ), but there were no differences in prevalence of myocardial infarction, stroke, major amputation or end stage renal disease (Table S2) .
When comparing the group of patients who were included based on the criteria above (see Methods section) and the availability of liver enzyme measurements (n = 9226) with those who fulfilled all inclusion criteria but for whom no liver enzyme measurements were available (n = 22 849), the patients with available liver enzyme measurements were younger, included a higher proportion of individuals with a migration background, had a higher BMI and waist circumference, higher HbA1c, higher daily insulin doses, lower triglyceride levels and lower blood pressure (Table S3) . Prevalence of MCI, stroke and end stage renal disease did not differ, but the prevalence of hypertension and dyslipidemia was higher in patients for whom liver enzymes have been reported (Table S3) .
Comparison between patients from centres in which liver enzymes were measured in > 50% of patients (n = 5073, 55%) and those from centres with less frequent liver enzyme measurements (n = 4153, 45%) showed that patients from centres with frequent liver enzyme measurements had a longer duration of diabetes, a higher proportion with migration background, higher HbA1c and higher systolic blood pressure (Table S4) . When analysing only data from centres that measure frequently, the proportion of patients with increased liver enzymes was 19.4%, which is similar to that reported in the total dataset (19.8%). The prevalence of MCI, stroke and major amputation did not differ, but there was a higher prevalence of end stage renal disease and hypertension in patients treated at centres with frequent measurement of liver enzymes (Table S4 ).
| DISCUSSION
In this report we describe the prevalence of increased liver enzymes For reports such as this to be useful for practicing clinicians, it is essential to put them in context. The prevalence of increased liver enzymes observed here compares to estimates of 10% to 21% in the general population [15] [16] [17] and 12% to 71% in individuals with type 2 diabetes. [18] [19] [20] [21] Comparing results from our study with data concerning the general population is difficult, because the latter may include, A smaller observational study in approximately 900 patients with T2DM and T1DM noted that ALT was increased in 2% to 35% of T1DM patients and 4% to 51% in T2DM patients, depending on the cut-off used. 22 In their subgroup with patients with T1DM, applying the same lower ALT threshold that we used in our subgroup analysis, 35% of patients had increased ALT, which is a higher proportion than in our cohort. 22 Another issue that arises in the analyses of large datasets is that no clear consensus as to where to set the cut-off thresholds for increased liver enzymes in T1DM exists; thus, the proportion of individuals with increased measurements depends on the diagnostic threshold applied. We have used different diagnostic criteria within the same DPV dataset, 1 applying national liver association guidelines and 1 using a lower ALT cut-off but in 2 measurements as suggested elsewhere. 12 Using these 2 approaches, the proportions of patients with elevated liver enzymes changes from 20% to 29%. However, the association with poorer glycaemic control and a less favourable cardiovascular risk profile (dyslipidemia and hypertension) was consistent in both analyses, whereas the association with diabetes complications (myocardial infarction and end stage renal disease) was significant only in the analysis applying the higher liver enzyme cut-off thresholds of the national guidelines. This would suggest that a lower ALT cut-off has the potential to identify patients with higher cardiovascular risk at an earlier stage.
In the present cross sectional analysis in individuals with T1DM in the DPV registry, the group with increased liver enzymes had a more adverse cardiovascular risk profile with a high prevalence of hypertension and dyslipidemia and worse glycaemic control than the group with normal liver enzymes. Patients with elevated liver enzymes were also more obese, suggesting a higher level of insulin resistance. Notably, the odds ratios for myocardial infarction and end stage renal disease were 1.5 and 1.6, respectively, when compared with patients with normal liver enzymes and after adjustment for age, HbA1c and other factors. This is in line with observations from a large, population-based, longitudinal study that suggested an association between elevated GGT levels and all-cause and cardiovascular mortality in men, 23 and from smaller clinic-based reports in individuals with T1DM in whom NAFLD was associated with an increased incidence of chronic kidney disease 24 and with a greater prevalence of retinopathy and nephropathy. Although the DPV has the potential to provide insight into routine clinical practice by virtue of its size, our study has obvious limitations. First, the real-world character of a clinical database is apparent in the 29% of patients for whom liver enzyme measurements were available. This heterogeneity of clinical practice among centres has the potential to introduce bias into our dataset. Patients for whom liver enzymes were not reported were younger, leaner, had better diabetes control and a lower prevalence of hypertension and dyslipidemia, which may have contributed to an individual clinician's decision not to measure liver enzymes. The additional comparison between patients from centres that measure liver enzymes in over 50% of patients and patients from centers that measure in less than 50% of patients confirmed that patients from centres with frequent liver enzyme measurements had a longer diabetes duration, worse diabetes control, were more likely to have a migration background and had a higher prevalence of hypertension and end stage renal disease, which altogether may have contributed to local clinical routine standards more in favour of a risk factor assessment including liver enzymes.
To conclude, in this clinical audit in adults with T1DM, elevated liver enzymes on routine clinical assessment were associated with a less favourable cardiovascular risk profile and poorer glycaemic control. We consider these observations worthy of reporting as they may, if supported by future longitudinal studies from other groups, provide an additional factor in the cardiovascular risk stratification of individuals with T1DM.
